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INTRODUCTION
Bone Remodeling
Bone is a specialized form of connective tissue that undergoes remodeling
throughout life. Bone remodeling is the continual cycle of breakdown and rebuilding of
bone that occurs in bone metabolism. It is a coupled process in which bone resorption is
followed by bone formation at the same site. This turnover mechanism is necessary so
that both skeletal structural integrity and the in homeostasis of calcium and phosphorous
are not compromised.
The basic multicellular unit (BMU) is made up of two principal cells involved in
bone remodeling, osteoblasts and osteoclasts. Osteoblasts are bone-forming cells and
osteoclasts are bone resorbing cells. Osteoblasts originate from pluripotent mesenchymal
stem cells of the bone marrow. Mesenchymal stem cells also carry the potential to
become fibroblasts, chondrocytes, adipocytes and muscle cells. It is believed that these
cells may represent different lineages arising from a pluripotent stem cell. With
stimulation via specific signals, these cells can proliferate and differentiate into
preosteoblasts, which may then become mature osteoblasts. Other cells of the osteogenic
lineage include lining cells and osteocytes, which are terminally differentiated
osteoblasts. Osteocytes are bone-forming osteoblasts that have become trapped in the
bone matrix that they produce. Lining cells are quiescent osteoblasts that are found
apposed to inactive bone surfaces (1, 2).
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2Morphologically, active osteoblasts are cuboidal cells that rarely undergo mitosis.
They possess cellular processes, gap junctions, abundant endoplasmic reticulum, Golgi,
and collagen-containing secretory vesicles localized on the matrix secreting side of the
cell. Osteoblasts contain alkaline phospatase (AP) in their plasma membrane; AP
regulates matrix mineralization and also serves as a phenotypic marker of the osteoblast
lineage. In addition, osteoblasts synthesize and secrete a number of other
macromolecules, which are incorporated into the matrix and mineralized over time to
form bone that is functionally and mechanically appropriate. Type I collagen is the major
protein of the bone matrix; noncollagen proteins include osteocalcin, osteonectin and
bone sialoprotein (3).
Osteoclasts are derived from henlatopoietic stem cells in the bone marrow,
specifically cells of the monocyte-macrophage lineage. Disruption of the c-fos gene and
the PU1 gene supports this origin since they result in severe osteopetrotic disorders from
defective osteoclast progenitors. The granulocyte-machrophage progenitors in human
marrow cultures (CFU-GM) have been thought to be the earliest identifiable osteoclast
precursors (4). Osteoclasts are multinucleated giant cells that are responsible for the
breakdown of bone. Active osteoclasts contain from four to twenty nuclei and are found
in or near cavities on bone surfaces called Howship's lacunae (5). The surface of the
osteoclast adjacent to the bone exhibits an area extensive membrane infolding termed the
ruffled border. This area is surrounded by a zone containing contractile proteins called
the sealing zone, which is the site of adhesion for osteoclasts. Osteoclasts express tartrate
3resistant acid phospatase (TRAP), calcitonin receptors, p60c-src, vitronectin receptors
(av~3), potassium proton ATPase, and cathepsin K (4).
Bone remodeling occurs in focal and discrete packets throughout the skeleton and
involves a series of carefully regulated events: local and systemic factors are released
upon hormonal or mechanical stimuli that enable preosteoclasts to differentiate into large,
multinucleated osteoclasts. In response to these signals, lining cells found on quiescent
bone surfaces undergo a shape change. They contract and release proteolytic enzymes to
expose the mineralized surface, which allows osteoclasts to access the bone's surface.
Once attached to bone, osteoclasts secrete hydrogen ions and lysosomal enzymes, which
enable the degradation of bone matrix. It is suspected that these osteoclasts undergo
apoptosis once resorption is complete. Macrophage-like mononuclear cells act to further
clear the area and deposit a proteoglycan-rich cement line, which demarcates the
resorption cavity. Finally, osteoblasts fill in the resorption cavity with osteoid that is
subsequently mineralized (1, 3).
Osteoclast Differentiation
It has been established by Takashashi and coworkers that the in vitro development
of macrophages into osteoclasts requires the presence of marrow stromal cells or their
osteoblast progeny (6). Recent studies have shown that osteoblast/stromal cells produce
two factors that are critical for osteoclast formation: macrophage colony-stimulating
factor (M-CSF) and receptor for activation of nuclear factor kappa B ligand (RANKL).
4M-CSF is a secreted protein; it binds to its receptor on osteoclast precursor cells and
initiates signals required for the proliferation of that cell (7). RANKL, on the other hand,
is a member of the TNF receptor family. It is expressed on osteoblasts/stromal cells and
directs the differentiation and activation of osteoclast through interaction with it's
receptor RANK, which is expressed on osteoclast precursor cells (4). Osteoprotegerin
(GPG), also a member of the TNF receptor family, functions as a decoy receptor. It is
secreted from osteoblasts/stromal cells and competes with RANK for RANKL. Hence,
the amount of bone resorption that will occur is determined by the relative amounts of
RANKL and GPG.
Insulin-like growth factors
Bone remodeling is regulated both by systemic hormones and local factors.
Among these, insulin-like growth factors (IGFs) play an important role. IGFs were
initially named for their insulin-like properties, but later their significance in mediating
the mitogenic effects of GH in skeletal growth became apparent. There are two known
forms oflGFs, IGF-I and IGF-II. These peptides are structurally similar to proinsulin,
with almost 50% amino acid sequence homology (8). Both IGFs are single-chain
polypeptides. Like insulin, they possess an A and B domain; however their C peptides
cannot be cleaved during prohormone processing. In addition, they contain aD-peptide
at the carboxy-terminus of the A domain (9).
5IGF-I is a peptide that functions as a mediator ofGH activity on longitudinal bone
growth. GH stimulates IGF-I production mainly by the liver as well as by non-hepatic
tissues. In nonhepatic tissues, IGF-I gene expression is regulated by tissue-specific
factors (10). In addition to its role in normal growth and development, IGF-I functions as
an a.nabolic factor for protein and carbohydrate metabolism. IGF-I also regulates cellular
activities involving cell proliferation, differentiation, and apoptosis (11). Such actions
require activation of the type 1 IGF-I receptor (IGFIR). This cell-surface receptor is a
transmembrane tyrosine kinase that is structurally similar to the insulin receptor (9). It is
composed of two a and two B subunits. The a subunits are entirely extracellular and
contain a cysteine rich region that is responsible for the high affinity IGF-I binding (12).
The B subunits include extracellular, transmembrane and cytoplasmic domains, which
contain the tyrosine kinase activity. The actions oflGFs are also modulated by IGF-
binding proteins (IGFBPs), which are found in circulation and in extracellular fluids (13).
These binding proteins influence the availability of IGF-I for receptor binding and
prolong the half-life ofIGFs by protecting them from proteolytic degradation.
IGF-I actions on bone
It is known that IGF-I is produced locally by osteoblasts and regulates osteoblast
proliferation and function. In addition, IGF-I increases type I collagen synthesis and rate
of bone matrix apposition and decreases collagen degradation (14-16). Moreover,IGF-1
maintains the ability of osteoblasts to express high alkaline phosphatase activity and
respond to PTH (17).
6The role that IGF-I plays on bone resorption, however, is less well understood.
IGFIRs have been identified on human preosteoclastic cells. Fiorelli et al. demonstrated
that IGF-I acts directly on these osteoclast precursor cells to stimulate their differentiation
into osteoclasts(18). In vitro studies of Hill et al. also demonstrated that IGF-I is able to
promote both osteoclast formation and activity, and hence stimulate bone resorption.
Contrary to these findings, however, studies by Jonsson et al showed that IGF-I has
inhibits agonist-stimulated bone resorption in cultured neonatal mouse calvariae (19).
The role IGFs in development and growth has been studied in transgenic mice
models with generalized IGF-I overexpression (20). Local actions ofIGFs have also
been studied using tissue-specific overexpression ofIGF-I. Reiss et al. used transgenic
mice in which overexpression ofIGF-I in heart was under the control of a rat a-myosin
heavy chain promoter. These mice showed an 84% increase in serum IGF-I levels. In
addition, an increase in heart weight and, the number ofmyocytes was detected. No
change in bone length and only very small increases in the weights of some organs were
seen (21), indicting that local expression ofIGF-I in heart selectively affected organ
growth.
To examine the effects of locally produced IGF-I in bone, transgenic mice with
overexpression ofIGF-I driven by the human osteocalcin promoter were used in studies
by Zhao et al (22). These mice demonstrated an increased bone formation rate by
approximately two-fold at 3 weeks of age and greater bone volume and density by six
weeks of age, during which time peak bone mass is achieved. There were no differences
7in cortical bone width. The increase in bone formation rate in these transgenic mice
occurred in the absence of increase in numbers if osteoblasts, osteocytes, or osteoclasts.
It was concluded by this model that the primary effect of locally produced IGF-I in bone
is to increase the activity of resident osteoblasts (22).
Recently, transgenic mice expressing IGF-I in bone under the influence of the
type I collagen promoter (Collal) were developed by Jiang et ale These mice show
evidence of increased bone turnover, including increased calvarial width, increased
calvarial marrow spaces and increased osteoclast number per bone surface. In
preliminary experiments, ex vivo bone marrow cultures from these mice produced more
osteoclasts. These data suggest that transgenic overexpression oflGF-1 may playa role
in increasing the number of osteoclast precursors in marrow (23, 24).
Significance to Orthodontics
In orthodontic treatment, teeth are displaced in bone in response to applied
mechanical forces. As a result, remodeling of the periodontal tissue surrounding the
tooth occurs. When a force is applied, the alveolar bone on the pressure side undergoes
successive cycles of bone resorption and formation, while bone on the tension side
undergoes continuous bone formation. The bone resorption that occurs is induced by a
complex process. As periodontal cells become compressed between the tooth and the
bony surface, they secrete bone-resorbing cytokines which stimulate osteoclast function
and bone resorption (25). In addition, there is recruitment of osteoclast precursor cells to
8the site that is to be resorbed. These precursor cells differentiate into mature osteoclasts,
adhere to the matrix, and undergo organization of the sealing zone and ruffled border.
Various hormonal and local factors are involved in this process, including parathyroid
hormone, 1,25-dihydroxyvitamin D3, interleukin-l, interleukin-6, and prostoglandins. In
addition to these factors, IGF-I may also play an important role in osteoclast formation
bone resorption that is seen in the remodeling that occurs during tooth movement.
GENERAL OBJECTIVE
Rationale and Hypothesis
Bone remodeling is regulated by systemic hormones and local growth factors.
IGF-I is a growth factor that is produced and secreted by the liver along with other tissues
in the body. In bone, IGF-I is produced locally and acts as an autocrine/paracrine growth
factor. The role ofIGF-I on bone remodeling and its therapeutic effect on bone mass has
been a recent interest amongst researchers today. Data, on the systemic administration of
IGF-I are conflicting regarding bone remodeling. A transgenic approach was used to
generate mice with osteoblast-directed IGF-I overexpression in order to assess a more
comprehensive effect ofIGF-I on bone remodeling. We hypothesize that alterations in
the production of IGF-I in vivo will stimulate osteoclast formation.
SPECIFIC OBJECTIVE
To examine osteoclast formation in bone marrow cultures from transgenic mice with
bone targeted IGF-I overexpression.
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METHODS AND MATERIALS
Materials and Animals
The materials used in this study were obtained from various sources. GlutaMAX
Media (aMEM) was purchased from Invitrogen Corporation (Carlsbad, CA). Fetal
bovine serum was purchased from Hyclone (Logan, Utah) and heat inactivated at 56°C
for 30 minutes. Penicillin-streptomycin was purchased from Sigma Chemicals Co. (St.
Louis, MO, U.S.A.) and prepared as a stock solutions containing 60 mg/ml penicillin and
50 mg/ml streptomycin. Glutamine was purchased from Invitrogen Corporation
(Carlsbad, CA). Forty-eight well tissue culture dishes were purchased from Costar
(Cambridge, MA). Mouse TRANCE (RANK Ligand) was purchased from R&D
Systems, Inc. (Westerville, OH) and resuspended in phosphate buffered solution (PBS)
with 0.1 % BSA. Mouse M-CSF (macrophage-colony stimulating factor) was purchased
from R&D Systems, Inc. (Westerville, OH).
The procedures for handling mice were performed in accordance to the guiding
principles of "Care and Use of Animals," found in the American Journal of Physiology.
All animal protocols were approved by the Animal Care Committee of the University of
Connecticut Health Center, Farmington, CT.
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Generation and peR Genotyping ofTransgenic Mice
Transgenic mice with osteoblast-targeted IGF-I overexpression (pOBCoI3.6-IGF)
were generated previously by embryo pronuclear injection in the institutional Transgenic
Animal Facility at University of Connecticut Health Center. The pOBCoI3.6-IGF
transgene is shown in Figure lA. It contains the rat Collal gene fragment from -3518 to
+1594 bp, including part of the first Collal exon and most of the first intron of Colla1,
murine IGF-I cDNA in which the FLAG epitope has been inserted between the signal
peptide and mature coding region ofIGF-I, and the bovine growth hormone
polyadenylation sequence.
The presence of the transgene in offspring was tested by PCR of tail DNA.
Transgenic lines were established by breeding the founders with CD-l wild-type mice
(Charles River Laboratories, Wilmington, MA). The Wizard genomic DNA extraction
kit (Promega, Madison, WI) was utilized to extract mouse tail genomic DNA. One cm
biopsies of mouse tails were washed before digestion in nuclear lysis solution, EDTA, pH
7.5, and Proteinase K. Tails were incubated overnight at 55°C. Then, 200 IJ,lofprotein
precipitation solution were added to each digest. The samples were mixed and
centrifuged, and the supernatant was poured into tubes containing isopropanol. Samples
were then centrifuged and the supernatant was decanted. The DNA pellet was washed
with 70% ethanol and air dried. PCR was performed with primers corresponding to the
first intron of the rat Collal gene (5'-ACCCTCCTCCATTTTAGCC) and the FLAG
sequence (5'-CATCGTCGTCCTTGTAGTC) (Figure lA). PCR (24-30 cycles) cycles
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were run at 94°C, 30 sec; 65°C, 30 sec; 72°C, 2 min. PCR products were fractionated by
electrophoresis on a 1% agarose gel and visualized by ethidium bromide staining.
Transgene DNA gave a 700 bp product in the PCR (Figure IB). The level of transgene
expression was assessed in different founder lines by analyzing the RNA by Northern
blotting. The ratio of transgene to actin expression of lines 98-572 and 99-324-7 were
1.1 and 2.0 (Figure 2). These lines have been previously designated as "intermediate"
and "high" expressing lines respectively (26).
Bone Marrow Cell Cultures
To generate experimental transgenic (TG) mice and wild type (WT) control
littermates, a hemizygous pOBCoI3.6-IGF mouse was bred with a CD-l wild type
mouse. Bone marrow cells were isolated from six to nine week old hemizygous TG and
WT male and female mice. Mice were sacrificed with C02 asphyxiation followed by
cervical dislocation. Mouse femurs and tibias were aseptically dissected. The ends of
each bone were cut off with a scissor. Once dissected, the marrow cavities were flushed
with aMEM. Marrow cells were collected by gentle centrifugation and washed twice
with aMEM. Cells were counted using a Coulter Counter (threshold of 8 J.1m), then
resuspended in 0.8 ml of aMEM containing 10% FBS. Cells were plated at 25,000
cells/well in 24-well tissue plates (Costar, Coming, NY) with and without RANKL (30
ng/ml) and M-CSF (30 ng/ml). The cells were cultured in a humidified atmosphere of 5%
CO2 in air at 37°C. The cultures were fed on day three by replacing old medium with
identical fresh medium. The day of take down of the cultures varied between day 3 to day
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7. In addition, time course experiments were performed in which cultures were assayed
for osteoclast formation daily from day 3 to day 7. Cells were then washed with PBS and
fixed with 2.5% glutaraldehyde in PBS for 30 minutes at room temperature. TRAP
staining was performed using the Leukocyte Acid Phosphatase Kit, (Sigma Corporation,
St. Louis, MO). TRAP-positive cells containing 3 or more nuclei were counted. Three
or four wells were analyzed for each culture condition.
Statistical Analysis
Data were analyzed with the Student's t-test or ANOVA, followed by the
Student-Newman-Keuls post-hoc test to determine whether there were statistical
differences among groups.
EXPERIMENTAL DESIGN
Two different pOBCoI3.6-IGF founder lines (98-572, and 99-324-7) were used
that express different levels of transgenic IGF-I. Line 99-324-7 expresses about three fold
more transgenic IGF-I mRNA than line 98-572. In each experiment, three to four wells
per group were analyzed. Each experiment was repeated at least twice to assess
reproducibility.
IEXPERIMENTAL GROUPS
WT + Vehicle
WT + RANKL and M-CSF
TG + Vehicle
TG + RANKL and M-CSF
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RESULTS
To examine the role of the IGF-I transgene on the formation osteoclastic cells,
defined as TRAP-positive multinucleated cells (MNC), we established ex vivo bone
marrow cultures form pOBCoI3.6-IGF TG mice and their WT littermates. In preliminary
experiments, the concentrations ofRANKL and M-CSF to be used were determined
empirically. Several dose-response experiments were performed in which the
concentrations ofRANKL and/or M-CSF were varied from 10 to 100 ng/ml: 10, 30, 60,
70, 90 and 100 ng/ml. Preliminary experiments were also performed in which the cell
plating density was varied to determine a satisfactory cell plating density for subsequent
experiments: 25,000-250,000 cells per well.
Based on these preliminary experiments, marrow from WT and two different lines
of TG mice (98-572 and 99-342-7) were plated at 25,000 cells/well and treated with
RANKL (30 ng/ml) and M-CSF (30 ng/ml) for up to seven days. TG lines 98-572 and
99-342-7, which has been designated "intermediate" and "high" expressing transgenic
lines, respectively, based on their level of transgene mRNA (Figure 2) and protein
expression (not shown).
Once the optimal concentration of factors and cell plating densities were
established, a series of experiments were performed to determine the role of transgenic
IGF-I on TRAP-positive MNC formation ex vivo cultures established from male and
female marrow of WT and TG mice of both lines. The length of take down of the
15
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cultures was variable, ranging between day 3 to day 7. This was in part based on the
visual assessment of the cultures by light microscopy for large osteoclastic cells.
First, we found that RANKL and M-CSF were required in bone marrow cultures
for TRAP-positive MNC formation. In the absence ofRANKL and M-CSF, no TRAP-
positive multinucleated cells (MNC) were observed in either TO or WT marrow in all
experiments. However, in the presence ofRANKL and M-CSF, TRAP-positive MNC
were formed in all experiments.
Next, we found that the effect of the IGF-I transgene on TRAP-positive MNC
formation in both male and female marrow was variable (Table 1). Some experiments
showed no significant difference between WT and TO marrow. Some experiments
showed an increase in the TO marrow, while others showed a decrease in TG marrow
(Tables 1 and 2). Some of the variability might have been due to the differing days of
takedown of the cultures.
Due to the variability of the results, several complete time course experiments
were performed from line 99-324-7 for both male and female transgenic and wild-type
mice. TRAP-positive MNC formation was determined daily for 5 days from day 3 to day
7. The quantitative data for TRAP-positive MNC formation are shown in Figures 3-7,
while the histological appearance of cells is shown in Figures 9-12. Figure 8 shows a
high power view of the intact TRAP-positive MNC seen in bone marrow cultures treated
with RANKL and M-CSF, and necrotic "ghosts" that were typical of older cultures.
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In experiment 17089 TRAP-positive MNC formation was significantly greater on
days 3-5 in marrow cultures from male TG mice compared to their WT littermates
(Figure 3). Peak TRAP-positive MNC formation was observed on day 4. The
appearance of necrotic cells was first detected on day 5 for both TO and WT groups.
However there appeared to be a greater number of necrotic cells in WT cultures. This
pattern was consistent until day 7 (Figure 9).
In experiment 17089, TRAP-positive MNC formation in female TO marrow was
significantly greater compared to their WT littermates on days 4-7 (Figure 4). Peak
TRAP-positive MNC formation was observed on day 5 for the TG mice, while the peak
for the WT mice was seen on day 4. Appearance of necrotic TRAP-positive MNC was
initially observed on day 5 for the WT females and on day 6 for TG females, with a
greater number seen in the WT cultures for the remaining days (Figure 10).
Experiments 17128 and 17144 showed similar results: TRAP-positive MNC
formation was significantly greater from TO mice than from WT littermates except in the
female group of experiment 17144. Here, TRAP-positive MNC in the TG group showed
a peak on day 6, which was slightly less than that of WT littermates. Nonetheless, when
complete time course experiments were performed, the data suggested that bone marrow
from IGF-I TG mice had an increased number of osteoclast precursors (Figures 11-12
and 5-7).
DISCUSSION
Bone remodeling is a process that involves a coupled sequence of bone resorption
and bone formation. The strength and integrity of bone relies on the balance between this
coupled process. In addition, it is necessary for the homeostasis of serum mineral levels.
IGF-I is an anabolic growth factor for bone formation. IGF-I is produced and secreted
primarily by the liver as well as other extrahepatic tissues including bone. In bone, IGF-I
acts in autocime/paracrine as a growth factor. The present study suggests that marrow
cells from transgenic mice femurs with osteoblast-directed overexpression oflGF-1 have
an increased number of osteoclast progenitor cells. The data was most consistent when
cultures were evaluated daily over a time course and showed much variability when
cultures evaluated at single time points. This data suggest that IGF-I affects osteoclast
formation.
It has recently been shown that osteoclast differentiation and activity is
dependent on signals form cells of the osteoblastic lineage(6). Direct cell-cell contact by
cells in the osteoblast lineage is necessary for the maturation of macrophages into
osteoclasts. These osteoblastic cells express the two molecules that are essential and
sufficient to promote osteoclastogenesis: receptor for activation or NF-KB lignad
(RANKL) and macrophage colony-stimulating factor (M-CSF) (27-30). RANKL has
been found to direct the differentiation and activation of osteoclasts by binding to its
receptor, RANK, located on the surface of osteoclast precursors (31). Osteoprotegerin
18
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(OPG) is a soluble receptor that is secreted by osteoblast/stromal cells. OPG provides
further regulation as it competes with RANK for RANKL. Recent studies suggest that
the ratio between RANKL and OPO expression in osteoblastic cells will determine the
amount of bone resorption that will occur (32). M-CSF is a secreted product that binds to
its receptor on the osteoclast precursor cells and initiates signals responsible for
proliferation. It is essential but not sufficient for osteoclastogenesis (12).
The multinucleated cells that formed in our bone marrow cultures expressed
tartrate-resistant acid phosphatase (TRAP). TRAP-positive multinucleated cell formation
in bone marrow cultures has been used as a measure of osteoclastogenesis. In order to
quantify osteoclast progenitors, cells were cultured with soluble RANKL and M-CSF.
These cytokines bypass the need for osteoblast support cells and are sufficient to
stimulate osteoclast formation in vitro (33). In our study, bone marrow cells from mice
femurs were cultured with maximally effective concentrations ofRANKL and M-CSF to
enable the differentiation of all osteoclast progenitors. Initial experiments of marrow
cultures from transgenic mice showed variability in TRAP-positive MNC formation
when compared marrow from wild-type littermates. These finding could be a result of
staining the cultures on selective days based on our assessment of unstained, vital
cultures. We suspect that we could have actually missed the day of peak TRAP-positive
MNC formation, which was probably different for the transgenic and wild-type groups.
Due to the variability observed in the results, time course experiments were later
performed to obtain a more complete picture of TRAP-positive MNC formation. These
experiments showed more consistent results. Here, marrow cultures from transgenic
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femurs showed increased formation of TRAP-positive MNC compared to wild-type
cultures. This is consistent with studies performed by Slootweg et al in which IGF-I was
found to stimulate the formation of osteoclast precursor and progenitor cells. As a result,
an increase in the number of osteoclasts in fetal metacarpals/metatarsals that contain only
precursor and progenitor osteoclastic cells was observed (34). Nonetheless, our findings
suggest that overexpression ofIGF-I in osteoblast/stromal cells in bone enhanced the
formation of osteoclast precursors. One reason for the finding in the time course
experiments could be due to a change in the media used to culture the cells. In all
experiments, alpha-MEM with the supplement Glutamax (a stable form of glutamine)
was used. However, additional glutamine was added to the media in the initial
experiments. Additional glutamine was not used in the time course experiments. Also to
be noted was the appearance of fewer necrotic osteoclastic cells (ghosts) in the transgenic
cultures versus wild-type cultures. We speculate that IGF-I may playa role in osteoclast
survival as well as osteoclast formation. Further experiments should be performed to
assess the role that IGF-I may play on enhancement of the lifespan of osteoclasts.
Another observation was the greater formation of TRAP-positive MNC observed in
female cultures relative to male cultures during the time course experiments. A
possibility for such findings could be due to the greater bone turnover in female mice.
There may be other mechanisms involved in the osteoclastogenesis observed in
our experiments. IGF-I has a mitogenic effect on stromal cells and osteoblasts in vitro
(35). It is possible the effects ofIGF-I could reflect an increase in the number of stromal
cells/osteoblasts that stimulate osteoclast formation. However, we used RANKL and M-
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CSF in marrow cultures to bypass the need for osteoblast support cells. This would argue
against an effect of transgenic IGF-I in vitro. In addition, IGF-I has been found to
increase IL-6 production in bone organ culture (34). IL-6 stimulates osteoclast
maturation and may be a mediator of other bone resorptive agents like PTH. Hence, IL-6
could be involved in bone resorption stimulated by IGF-I.
Nonetheless, this study suggests that IGF-I may playa role in increasing bone
resorption by increasing the number of osteoclast progenitors in bone marrow. To
investigate this further, knockout of the murine IGF-I receptors in the bone
microenvironment (osteoblasts and osteoclasts) may be an additional experimental model
in which to evaluate the role ofIGF-I on osteoclastogenesis. In our study, we did not
evaluate the activity of TRAP-positive MNC formed in marrow cultures. This may be
achieved by measuring pit formation activity of TRAP-positive MNC on dentin slices.
Results of such a study may help determine ifIGF-I affects the activity of TRAP-positive
MNC as well as their formation.
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Figure 1. Schematic diagram of the pOBCoI3.6-IGF transgene and PCR genotyping of
mIce
A) The pOBCoI3.6-IGF transgene contains the rat Collal gene fragment from-3518 to
+1594 bp, including part of the first Collal exon and most of the first intron of Colla1
(CoI3.6), murine IGF-I cDNA (IGF-I) in which the FLAG (FL) epitope was inserted
between the signal peptide (SP) and mature coding region ofIGF-I, and the bovine
growth hormone polyadenylation sequence (pA). PCR genotyping was carried out using
primers corresponding to regions of the Collal first intron (INT) and the FLAG
sequence, which generate a unique 700 bp transgene product. The sequence of the
primers are given in Materials and Methods.
B) PCR genotyping of mice that were generated by breeding a hemizygous transgenic
(TG) mouse with a wild-type (WT) mouse. DNA was extracted from mouse tails and
amplified by PCR as described in the Methods and Materials. M, 0X molecular weight
size markers. Lanes 1-7, PCR analysis of tail DNA showing TG and WT offspring.
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Figure 2. Transgene expression in ealvariae of the different pOBCoI3.6-IGF lines using
in the present study. Transgene expression in lines 98-572 (572) and 99-324-7 (324-7)
was determined by Northern blotting with an IGF-I eDNA probe. The blots were also
probed with an aein eDNA. The numbers shown below the lanes are the IGF-I transgene
signal normalized to the actin signal.
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Figure 3. Time course of formation of TRAP-positive multinucleated cells (MNC) in ex
vivo bone marrow cultures from wild-type (WT) and transgenic (TG) male mice (line 99-
324-7). Marrow was cultured with RANKL (30 ng/ml) and M-CSF (30 ng/ml) for up to
7 days. At each day of takedown, cultures were stained for TRAP as described in
Materials and Methods. TRAP-positive cells containing more than 3 nuclei were
counted. Each value is a mean ± SEM of 4 wells. *Different from WT, P<0.05. Data
shown are from experiment 17089.
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Figure 4. Time course of formation of TRAP-positive multinucleated cells (MNC) in ex
vivo bone marrow cultures from wild-type (WT) and transgenic (TO) female mice (line
99-324-7). Marrow was cultured with RANKL (30 ng/ml) and M-CSF (30 ng/ml) for up
to 7 days. At each day of takedown, cultures were stained for TRAP as described in
Materials and Methods. TRAP-positive cells containing more than 3 nuclei were
counted. Each value is a mean ± SEM of 4 wells. *Different from WT, P<0.05. Data
shown are from experiment 17089.
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Figure 5. Time course of formation of TRAP-positive multinucleated cells (MNC) in ex
vivo bone marrow cultures from wild-type (WT) and transgenic (TG) male mice (line 99-
324-7). Marrow was cultured with RANKL (30 ng/ml) and M-CSF (30 ng/ml) for up to
7 days. At each day of takedown, cultures were stained for TRAP as described in
Materials and Methods. TRAP-positive cells containing more than 3 nuclei were
counted. Each value is a mean ± SEM of 4 wells. *Different from WT, P<0.05. Data
shown are from experiment 17144.
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Figure 6. Time course of formation of TRAP-positive multinucleated cells (MNC) in ex
vivo bone marrow cultures from wild-type (WT) and transgenic (TG) female mice (line
99-324-7). Marrow was cultured with RANKL (30 ng/ml) and M-CSF (30 ng/ml) for up
to 7 days. At each day of takedown, cultures were stained for TRAP as described in
Materials and Methods. TRAP-positive cells containing more than 3 nuclei were
counted. Each value is a mean ± SEM of 4 wells. *Different from WT, P<0.05. Data
shown are from experiment 17144.
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Figure 7. Time course of formation of TRAP-positive multinucleated cells (MNC) in ex
vivo bone marrow cultures from wild-type (WT) and transgenic (TG) female mice (line
99-324-7). Marrow was cultured with RANKL (30 ng/ml) and M-CSF (30 ng/ml) for up
to 7 days. At each day of takedown, cultures were stained for TRAP as described in
Materials and Methods. TRAP-positive cells containing more than 3 nuclei were
counted. Each value is a mean ± SEM of 4 wells. *Different from WT, P<0.05. Data
shown are from experiment 17128.
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Figure 8. Histological appearance of TRAP-positive multinucleated cells (MNC) formed
in ex vivo bone marrow cultures. Note the intact TRAP-positive MNC (black arrowhead)
and necrotic MNC (yellow arrowhead).
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Figure 9. Histological appearance of TRAP-positive multinucleated cells in ex vivo bone
marrow cultures from wild-type and transgenic male mice (line 99-324-7) over a seven
day time course. Marrow was cultured for 7 days with RANKL (30 ng/ml) and M-CSF
(30 ng/ml) and stained for TRAP as described in the Methods and Materials. Cultures
were analyzed each day from day 3 to day 7. Images shown are from experiment 17089.
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Figure 10. Histological appearance of TRAP-positive multinucleated cells in ex vivo
bone marrow cultures from wild-type and transgenic female mice (line 99-324-7) over a
seven day time course. Marrow was cultured for 7 days with RANKL (30 ng/ml) and
M-CSF (30 ng/ml) and stained for TRAP as described in the Methods and Materials.
Cultures were analyzed each day from day 3 to day 7. Images shown are from
experiment 17089.
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Figure 11. Histological appearance of TRAP-positive multinucleated cells in ex vivo
bone marrow cultures from wild-type and transgenic male mice (line 99-324-7) over a
seven day time course. Marrow was cultured for 7 days with RANKL (30 ng/ml) and
M-CSF (30 ng/ml) and stained for TRAP as described in the Methods and Materials.
Cultures were analyzed each day from day 3 to day 7. Images shown are from
experiment 17144.
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Figure 12. Histological appearance of TRAP-positive multinucleated cells in ex vivo
bone marrow cultures from wild-type and transgenic female mice (line 99-324-7) over a
seven day time course. Marrow was cultured for 7 days with RANKL (30 ng/ml) and
M-CSF (30 ng/ml) and stained for TRAP as described in the Methods and Materials.
Cultures were analyzed each day from day 3 to day 7. Images shown are from
experiment 17144.
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Table 1. Quantification of TRAP-positive multinucleated cells in bone marrow cultures
from male (m) and female (f) wild-type (WT) and transgenic (TG) mice from lines 98-
572 and 99-342-7. Marrow was cultured with RANKL (30 ng/ml) and M-CSF (30
ng/ml). Cultures were stained for TRAP between day 3 to day 7 as indicated. TRAP-
positive cells containing more than 3 nuclei were counted. Each value is a mean ± SEM
of 3-4 wells. *Different from the respective WT group, P<0.05. ND, not determined.
TD, takedown.
Line Expt # Day of
TD
WT-m TG-m WT-f TG-f
98-572 16844 3 952 ± 152 550 ± 58 ND ND
16854 3 610 ± 56 628 ± 55 ND ND
16869 6 379± 115 254 ± 66 614±81 308 ± 41 *
16882 5 101 ± 20 550 ± 39* 639 ± 63 438 ± 43*
16948 4 1307 ± 71 730 ± 39* 925 ± 39 689 ± 54*
99-342-7 16705 4 1080 ± 63 997 ± 252 952 ± 54 738 ± 23*
16844 3 ND ND 570 ± 79 286 ± 39*
16914 4 957 ± 38 534 ± 42* 372 ± 89 1168±53*
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Table 2. Quantification of TRAP-positive multinucleated cells in bone marrow cultures
from male (m) and female (f) wild-type (WT) and transgenic (TG) mice from line 99-
342-7. Marrow was cultured with RANKL (30 ng/ml) and M-CSF (30 ng/ml). Cultures
were stained for TRAP on the days indicated. TRAP-positive cells containing more than
3 nuclei were counted. Each value is a mean ± SEM of 3-4 wells. *Different from the
respective WT group, P<0.05. TD, takedown.
Line Expt# Day of WT-m TG-m WT-f TG-f
TD
99-324-7 16979 5 886 ± 63 783 ± 78 440 ± 37 441 ± 32
16979 7 100 ± 14 452 ± 53* 441 ± 53 620 ± 110
17024 4 681 ± 36 854 ± 20* 781 ± 36 602 ± 48*
17024 6 233 ± 33 86 ± 12* 221 ± 50 163 ± 20
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